Literature DB >> 30219841

Strengthen Village Malaria Reporting to Better Target Reservoirs of Persistent Infections in Southeast Asia.

Thomas J Peto1,2, Rupam Tripura1,2, Richard J Maude1,2,3.   

Abstract

Entities:  

Keywords:  Southeast Asia; asymptomatic infection; community health worker; elimination; malaria

Year:  2019        PMID: 30219841      PMCID: PMC6399432          DOI: 10.1093/cid/ciy793

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


× No keyword cloud information.
To the Editor—The recent World Health Organization malaria surveillance, monitoring, and evaluation manual highlights the importance that strengthened community health worker (CHW) programs and their ability to report accurate and timely data hold for the elimination of malaria [1]. Mass Drug Administration (MDA) is proposed as a means of interrupting Plasmodium falciparum transmission in areas of emergent, multidrug-resistant parasites [2, 3]. The 2017 World Health Organization recommendations on MDA inform control programs how to implement this strategy, but there is no specific advice on how to target suitable populations in Southeast Asia [4, 5]. Since 2013, we have conducted population-based surveys to define the micro-epidemiology of asymptomatic malaria infections and have piloted MDA in Southeast Asia [6]. Asymptomatic P. falciparum infections persist, on average, for several months, with varying parasite densities that are periodically capable of transmission [7]. Our experience is that prevalence surveys are an expensive and time-consuming means of identifying foci of transmission in pre-elimination (low-transmission) settings, particularly where highly-sensitive molecular techniques are used to detect asymptomatic infections. Currently, CHWs are active in many more villages than could be practicably included in a baseline prevalence survey, but are well positioned—with strengthening of the reporting system where needed—to routinely collect travel and residency data to determine whether individual locations are sources where transmission occurs or sinks where cases are reported but not acquired. If of sufficient quality, CHW data could be used to identify locations for targeted MDA, such as village clusters where the P. falciparum incidence is above a locally-defined threshold. High-quality incidence data has been shown to be predictive of asymptomatic carriage rates in low-transmission settings, thus potentially obviating the need to screen populations using more expensive molecular methods to define targets for MDA [8]. Incidence data determined from reliable case reporting could also be the preferred metric to evaluate the impact of MDA. For example, a recent elimination program in Myanmar demonstrated a rapid decline in the incidence of malaria following the implementation of a strong village malaria worker network, demonstrating the effectiveness of conducting an MDA in a transmission hotspot [9]. In Southeast Asia, asymptomatic Plasmodium vivax infections are even more under-detected and undertreated than P. falciparum [10]. In our studies, a history of clinical malaria was a consistently strong risk factor for persistent asymptomatic infection. In a prior survey, we matched participants to treatment records and found that approximately a third of people with a history of clinical P. vivax were parasitaemic [11]. Therefore, local health services already have recorded the names and locations of thousands of people harboring P. vivax infections that contribute to ongoing transmission. These people could be screened for G6PD deficiencies and offered safe treatment with primaquine for radical cures of liver-stage parasites. Targeting persistent P. vivax from treatment records alone would neither catch all carriers nor interrupt transmission, but could treat an important fraction of extant P. vivax infections and represent a move from P. vivax control towards elimination. As countries progress towards elimination, investments in strengthening and expanding the coverage of CHW programs and case reporting are vital. Making better use of this data could identify persistent infections at both the community and individual levels, allowing for the targeting of elimination strategies that address the asymptomatic reservoir and for new screen-and-treat strategies, which may become viable with the deployment of highly-sensitive rapid diagnostics.
  8 in total

Review 1.  Fighting fire with fire: mass antimalarial drug administrations in an era of antimalarial resistance.

Authors:  Lorenz von Seidlein; Arjen Dondorp
Journal:  Expert Rev Anti Infect Ther       Date:  2015-04-01       Impact factor: 5.091

2.  Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance.

Authors:  Richard J Maude; Duong Socheat; Chea Nguon; Preap Saroth; Prak Dara; Guoqiao Li; Jianping Song; Shunmay Yeung; Arjen M Dondorp; Nicholas P Day; Nicholas J White; Lisa J White
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

3.  Submicroscopic Plasmodium prevalence in relation to malaria incidence in 20 villages in western Cambodia.

Authors:  Rupam Tripura; Thomas J Peto; Christianne C Veugen; Chea Nguon; Chan Davoeung; Nicola James; Mehul Dhorda; Richard J Maude; Jureeporn Duanguppama; Krittaya Patumrat; Mallika Imwong; Lorenz von Seidlein; Martin P Grobusch; Nicholas J White; Arjen M Dondorp
Journal:  Malar J       Date:  2017-01-31       Impact factor: 2.979

4.  Effect of generalised access to early diagnosis and treatment and targeted mass drug administration on Plasmodium falciparum malaria in Eastern Myanmar: an observational study of a regional elimination programme.

Authors:  Jordi Landier; Daniel M Parker; Aung Myint Thu; Khin Maung Lwin; Gilles Delmas; François H Nosten
Journal:  Lancet       Date:  2018-04-24       Impact factor: 202.731

5.  A Controlled Trial of Mass Drug Administration to Interrupt Transmission of Multidrug-Resistant Falciparum Malaria in Cambodian Villages.

Authors:  Rupam Tripura; Thomas J Peto; Nguon Chea; Davoeung Chan; Mavuto Mukaka; Pasathorn Sirithiranont; Mehul Dhorda; Cholrawee Promnarate; Mallika Imwong; Lorenz von Seidlein; Jureeporn Duanguppama; Krittaya Patumrat; Rekol Huy; Martin P Grobusch; Nicholas P J Day; Nicholas J White; Arjen M Dondorp
Journal:  Clin Infect Dis       Date:  2018-08-31       Impact factor: 9.079

6.  History of malaria treatment as a predictor of subsequent subclinical parasitaemia: a cross-sectional survey and malaria case records from three villages in Pailin, western Cambodia.

Authors:  Thomas J Peto; Sabine E Kloprogge; Rupam Tripura; Chea Nguon; Nou Sanann; Sovann Yok; Chhouen Heng; Cholrawee Promnarate; Jeremy Chalk; Ngak Song; Sue J Lee; Yoel Lubell; Mehul Dhorda; Mallika Imwong; Nicholas J White; Lorenz von Seidlein; Arjen Dondorp
Journal:  Malar J       Date:  2016-04-26       Impact factor: 2.979

7.  Point-of-care G6PD diagnostics for Plasmodium vivax malaria is a clinical and public health urgency.

Authors:  J Kevin Baird
Journal:  BMC Med       Date:  2015-12-14       Impact factor: 8.775

8.  The persistence and oscillations of submicroscopic Plasmodium falciparum and Plasmodium vivax infections over time in Vietnam: an open cohort study.

Authors:  Thuy-Nhien Nguyen; Lorenz von Seidlein; Tuong-Vy Nguyen; Phuc-Nhi Truong; Son Do Hung; Huong-Thu Pham; Tam-Uyen Nguyen; Thanh Dong Le; Van Hue Dao; Mavuto Mukaka; Nicholas Pj Day; Nicholas J White; Arjen M Dondorp; Guy E Thwaites; Tran Tinh Hien
Journal:  Lancet Infect Dis       Date:  2018-02-02       Impact factor: 71.421

  8 in total
  1 in total

1.  Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia.

Authors:  Bipin Adhikari; Rupam Tripura; Lek Dysoley; James J Callery; Thomas J Peto; Chhoeun Heng; Thy Vanda; Ou Simvieng; Sarah Cassidy-Seyoum; Benedikt Ley; Kamala Thriemer; Arjen M Dondorp; Lorenz von Seidlein
Journal:  Malar J       Date:  2022-10-04       Impact factor: 3.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.